Abstract
l-Stepholidine (SPD) is a tetrahydroprotoberberine alkaloid and a mixed dopamine D1 agonist/D2 antagonist. Preliminary clinical trials suggest that SPD improves both positive and negative symptoms of schizophrenia without producing significant extrapyramidal side effects. Here, we report that SPD mimics the effect of the atypical antipsychotic drug clozapine, preferentially increasing Fos expression in corticolimbic areas. Thus, at 10 mg/kg (i.p.), SPD induced Fos expression in the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), and lateral septal nucleus (LSN) without significantly affecting the dorsolateral striatum (DLSt). At higher doses (20–40 mg/kg), SPD also increased Fos expression in the DLSt. The increase, however, was less pronounced than the increase seen in the NAc. Within the NAc, SPD also induced more Fos expression in the shell than in the core. In all subcortical areas examined, the Fos expression induced by SPD was mimicked by the D2 antagonist sulpiride and reversed by the D2 agonist quinpirole, suggesting that the effect is due to blockade of D2-like receptors by SPD. In the mPFC, however, the effect was not mimicked by sulpride or reversed by quinpirole. It was also not mimicked by the D1 agonist SKF38393 or SKF38393 plus sulpride, and not reversed by the D1 antagonist SCH23390. These results suggest that, in the mPFC, SPD may induce Fos expression through a non-DA mechanism. Whether the mechanism involves an interaction of SPD with other neurotransmitters such as 5-HT and norepinephrine remains to be determined.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Alonso R, Gnanadicom H, Frechin N, Fournier M, Le Fur G, Soubrie P (1999). Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain. Eur J Neurosci 11: 967–974.
Brog JM, Deutch A, Zahm D (1991). Afferent projections to the nucleus accumbens core and shell in the rat. Soc Neurosci Abstr 41: 89–126.
Cai N, Jin G, Zhang ZD (1988). A controlled study on the treatment of tardive dyskinesia using 1-stepholidine. Zhonghua Shen Jing Jing Shen Ke Za Zhi 21: 281–283.
Deutch AY (1994). Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. J Clin Psychiatry 55 (Suppl B): 37–42.
Deutch AY, Duman RS (1996). The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70: 377–389.
Deutch AY, Moghaddam B (1992). Regionally specific effects of atypical antipsychotic duugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3: 332–341.
Diaz Heijtz R, Scott L, Forssberg H (2004). Alteration of dopamine D1 receptor-mediated motor inhibition and stimulation during development in rats is associated with distinct patterns of c-fos mRNA expression in the frontal–striatal circuitry. Eur J Neurosci 19: 945–956.
Dong ZJ, Guo X, Chen LJ, Han YF, Jin GZ (1997). Dual actions of (–)-stepholidine on the dopamine receptor-mediated adenylate cyclase activity in rat corpus striatum. Life Sci 61: 465–472.
Dragunow M, Robertson GS, Faull RL, Robertson HA, Jansen K (1990). D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 37: 287–294.
Fibiger HC (1994). Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. J Clin Psychiatry 55 (Suppl B): 33–36.
Glickstein SB, Hof PR, Schmauss C (2002). Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. J Neurosci 22: 5619–5629.
Guo X, Ding YM, Hu JY, Jin GZ (1998). Involvement of dopamine D1 and D2 receptors in Fos immunoreactivity induced by stepholidine in both intact and denervated striatum of lesioned rats. Life Sci 62: 2295–2302.
Huang K, Jin G (1992). The antagonistic effects of tetrahydroprotoberberines on dopamine receptors: electrophysiological studies. Sci China B 35: 688–696.
Jin G, Xu S, Yu L (1987). Tetrahydropalomatine and its analogues as new dopamine receptor antagonists. Trends Pharmacol Sci 8: 81–82.
Jin GZ, Huang KX, Sun BC (1992). Dual actions of (−)-stepholidine on dopamine receptor subtypes after substantia nigra lesion. Neurochem Int 20 (Suppl): 175S–178S.
Jin GZ, Sun BC (1995). Neuropharmacological effects of (−)-stepholidine and its analogues on brain dopaminergic system. Adv Exp Med Biol 363: 27–28.
Jin GZ, Zhu ZT, Fu Y (2002). Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends Pharmacol Sci 23: 4–7.
Lei S, Orensanz LM, Mulvany MJ, Simonsen U (1999). Mechanisms involved in the vasorelaxant effect of (−)-stepholidine in rat mesenteric small arteries. Eur J Pharmacol 365: 193–204.
Miller JC (1990). Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J Neurochem 54: 1453–1455.
National Research Council (1996). Guide for the Care and Use of Laboratory Animals. National Academy Press: Washington, DC.
Ohashi K, Hamamura T, Lee Y, Fujiwara Y, Suzuki H, Kuroda S (2000). Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-adrenoceptors. Neuropsychopharmacology 23: 162–169.
Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney.
Robertson GS, Fibiger HC (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46: 315–328.
Robertson GS, Fibiger HC (1996). Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 14: 105–110.
Robertson GS, Matsumura H, Fibiger HC (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271: 1058–1066.
Shi WX, Chen Y, Jin GZ (1984). Effect of l-stepholidine on rotational behavior in rats. Acta Pharmacol Sin 5: 222–225.
Weinberger DR (1988). Schizophrenia and the frontal lobe. Trends Neurosci 11: 367–370.
Wu DC, Xing XZ, Wang WA, H X, Wang HH, Wang XY, Cong Z, Jin GZ (2003). A double blind comparison trial of L-stepholidine and perphenazine in treatment of schizophrenia. Chin J New Drugs Clin 22: 155–160.
Xu SX, Yu LP, Han YR, Chen Y, Jin GZ (1989). Effects of tetrahydroprotoberberines on dopamine receptor subtypes in brain. Zhongguo Yao Li Xue Bao 10: 104–110.
Zou LL, Liu J, Jin GZ (1997). Involvement of receptor reserve in D1 agonistic action of (−)-stepholidine in lesioned rats. Biochem Pharmacol 54: 233–240.
Acknowledgements
This work was supported by National Basic Research Program of China (973 Program) ‘2003CB515400’, National Natural Science Fund ‘30230130’ and ‘30271495’.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mo, YQ., Jin, XL., Chen, YT. et al. Effects of l-Stepholidine on Forebrain Fos Expression: Comparison with Clozapine and Haloperidol. Neuropsychopharmacol 30, 261–267 (2005). https://doi.org/10.1038/sj.npp.1300628
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300628
Keywords
This article is cited by
-
Levo-tetrahydropalmatine inhibits α4β2 nicotinic receptor response to nicotine in cultured SH-EP1 cells
Acta Pharmacologica Sinica (2022)
-
Dopamine D1 and D2 receptors mediate analgesic and hypnotic effects of l-tetrahydropalmatine in a mouse neuropathic pain model
Psychopharmacology (2019)
-
The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist
Psychopharmacology (2008)
